Home › All Companies › ALNY › Annual Report

ALNYLAM PHARMACEUTICALS, INC. (ALNY) — Annual Report

AI-Powered SEC Filing Analysis

← All ALNY filings
Latest Annual Report Filed: 2026-02-12

Key Insights

  • Alnylam's total revenue is expected to grow significantly from 2023 to 2025, driven by increasing sales of key products like Amvuttra and Onpattro.
  • Gross margins are projected to improve over the same period, indicating increasing operational efficiency.
  • The company has convertible debt due in 2027 and 2028, which could impact its capital structure and liquidity in the coming years.
Sentiment: Positive Significance: 7/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-02-12. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for ALNYLAM PHARMACEUTICALS, INC.

Insider Trading Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.